PLA2G7 Human
Description
The PLA2G7 is purified by proprietary chromatographic techniques.
Product Specs
PLA2G7 is believed to play a role in the development of atherosclerosis and serves as a marker for cardiac disease. It may have significant physiological effects during inflammatory responses within the body.
By hydrolyzing the sn-2 ester bond, PLA2G7 modifies the activity of platelet-activating factor (PAF), resulting in the formation of lyso-PAF, an inactive form. This enzyme exhibits specificity for substrates with a short residue at the sn-2 position and remains inactive against long-chain phospholipids.
Genetic defects in the PLA2G7 gene can lead to platelet-activating factor acetylhydrolase deficiency, a condition found in approximately 27% of the Japanese population.
The purification of PLA2G7 is achieved using proprietary chromatographic techniques.
For long-term storage, freeze at -20°C.
Repeated freezing and thawing should be avoided.
Product Science Overview
Secreted Phospholipase A2-VII (sPLA2-VII), also known as Group VIIA PLA2 or Platelet-activating factor acetylhydrolase (PAF-AH), is an enzyme that belongs to the phospholipase A2 superfamily. This enzyme plays a crucial role in lipid metabolism and inflammatory processes by hydrolyzing phospholipids to release fatty acids and lysophospholipids .
sPLA2-VII is a low molecular mass enzyme that requires calcium ions (Ca2+) for its activity. It has a conserved His-Asp catalytic dyad, which is essential for its enzymatic function . The enzyme specifically targets the sn-2 position of glycerophospholipids, leading to the production of arachidonic acid and lysophosphatidylcholine . These products are precursors for various bioactive lipid mediators, including prostaglandins and leukotrienes, which are involved in inflammatory and immune responses .
sPLA2-VII is involved in several physiological and pathological processes:
- Inflammation: sPLA2-VII is known to promote inflammation by catalyzing the first step of the arachidonic acid pathway . This pathway leads to the production of pro-inflammatory mediators that play a role in various inflammatory diseases.
- Atherosclerosis: The enzyme has been implicated in the development of atherosclerosis by hydrolyzing low-density lipoprotein (LDL) to produce pro-atherogenic particles . These particles promote the formation of macrophage foam cells, a hallmark of atherosclerotic plaques.
- Metabolic Disorders: Recent studies have shown that sPLA2-VII is involved in metabolic disorders such as obesity, diabetes, and hepatic steatosis . The enzyme’s activity affects lipid metabolism and contributes to the development of these conditions.
Due to its involvement in inflammation and atherosclerosis, sPLA2-VII is considered a potential therapeutic target for treating inflammatory diseases and cardiovascular disorders . Inhibitors of sPLA2-VII are being explored for their potential to reduce inflammation and prevent the progression of atherosclerosis.
